ANALGESIC POTENTIAL OF PURINE RECEPTOR AGONISTS AND B VITAMINS IN THE TREATMENT OF DIABETIC POLYNEUROPATHY
https://doi.org/10.30895/1991-2919-2018-8-1-17-22
Abstract
The efficacy and safety of purine receptor agonists in patients with chronic pain have been analysed. The data on the clinical application of purine analgesia in the management of pain syndrome are reviewed. The use of purine analgesia for the treatment of patients with chronic neuropathic pain is scientifically justified. The central mechanisms of purine receptor agonists and their analgesic activity are described in detail. It has been shown that purine receptor agonists have a strong analgesic effect and a narrow range of side effects, and they effectively relieve neuropathic pain by influencing the purinergic regulatory mechanism. The mechanisms of the analgesic effect of B vitamins (B1, B6, B12) that have their own analgesic potential are considered — which is of great importance in the pharmacotherapy of polyneuropathies. It should be noted that the prescription of B vitamins is pathogenetically justified in diabetic polyneuropathy, and a combination of B vitamins is more efficacious than a monotherapy.
About the Authors
O. A. Demidova
Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Olga A. Demidova - Research Associate of the Department of Drug Interactions and Rational Pharmacotherapy of the Clinical Pharmacology Centre, Candidate of Pharmaceutical Sciences.
8/2 Petrovsky boulevard, Moscow 127051E. V. Shikh
Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Evgenia V. Shikh - Leading Research Associate of the Department of Personalised Medicine and Clinical Pharmacogenetics of the Clinical Pharmacology Centre, Doctor of Medical Sciences, Professor.
8/2 Petrovsky boulevard, Moscow 127051
References
1. Bukatina TM, Kazakov AS, Kaperko DA, Romanova TV. Canagliflozin and risk of amputation in patients with type 2 diabetes. Safety and Risk of Pharmacotherapy 2017; 5(3): 100-3 (In Russ.)
2. Galieva OR, Dzhanashiya PH, Mirina EYu. Treatment of diabetic neuropathy. International Journal of Neurology 2008; (1): 77-81 (In Russ.)
3. Gratsianskaya AN. The treatment of diabetic polyneuropathy. Difficult Patient 2009; 7(8-9): 47-50 (In Russ.)
4. Javed S, Petropoulos IN, Alam U, Malik RA. Treatment of painful diabetic neuropathy. Ther Adv Chronic Dis. 2015; 6(1): 15-28.
5. Burnstock G. Co-transmission. Arch Int Pharmacodyn Ther. 1990; (304): 7-33.
6. Pelleg A, Belhassen B, Ilia R, Laniado S. Comparative electrophysiologic effects of adenosine triphosphate and adenosine in the canine heart: influence of atropine, propranolol, vagotomy, dipyridamole and aminophylline. Am J Cardiol. 1985; 55(5): 571-6.
7. Robinson DA, Wang P, Chaudry JH. Administration of ATP-MgCl2 after trauma haemorrhage and resuscitation restores the depressed cardiac performance. J Surg Res. 1997; 69(1): 159-65.
8. Li X, Eisenach JC. Adenosine reduces glutamate release in rat spinal synaptosomes. Anesthesiology 2005; 103(5): 1060-5.
9. Karelov AE, Zakharov DA, Lebedinsky KM, Semenov DA. New technologies in anesthesiology: purine analgesia. Vestnik of Saint Petersburg University 2008; (S1): 77-82 (In Russ.)
10. Robinson DA, Wang P, Chaudry JH. Administration of ATP-MgCl2 after trauma haemorrhage and resuscitation restores the depressed cardiac performance. J Surg Res. 1997; 69(1): 159-65.
11. Kozlovsky VA, Shmaliy VI. ATP as an instant messenger and a messenger as a target of therapeutic effects. Medicines of Ukraine 2008; (3): 48-52 (In Russ.)
12. Karelov AE, Lebedinsky KM. Analgesic adjuvants or alternative analgesic. Messenger of Anesthesiology and Resuscitation 2013; 10(6): 72-80 (In Russ.)
13. Handa T, Fukuda K, Hayashida M, Koukita Y, Ichinohe T, Kaneko Y. Effects of intravenous adenosine 5’-triphosphate on intraoperative hemodynamics and postoperative pain in patients undergoing major orofacial surgery: a double-blind placebo-controlled study. J Anesth. 2009; 23(3): 315-22.
14. Segerdahl M, Karelov A. Experimentally induced ischaemic pain in healthy humans is attenuated by the adenosine receptor antagonist theophylline. Acta Physiol Scand. 2004; 180(3): 301-6.
15. Karelov AE, Aleeva RSh, Gorokhov KA, Patlay IV. Effects of activation and blockade of the purine receptors with strony nociceptive stimulation in awake volunteers. Efferent Therapy 2010; 16(3): 86-90 (In Russ.)
16. Belfrage M, Sollevi A, Segerdahl M, Sjolund KF, Hansson P. Systemic adenosine infusion alleviates spontaneous and stimulus evoked pain in patients with peripheral neuropathic pain. Anesth Analg. 1995; 81(4): 713-7.
17. Borsook D, Kussman BD, George E, Becerra LR, Burke DW. Surgically induced neuropathic pain: understanding the perioperative process. Ann Surg. 2013; 257(3): 403-12.
18. Partseva NO, Danilova AV, Pastarus LN. The strategy of complex pathogenetic treatment of diabetic neuropathy. International Journal of Endocrinology 2012; (7): 33-5 (In Russ.)
19. Wang ZB, Gan Q, Rupert RL, Zeng YM, Song XJ. Thiamine, pyridoxine, cyanocobalamin and their combinatuin inhibit thermal, but not mechanical hyperalgesia in rats with primary sensory neuron loss. Pain 2005; 114(1-2): 266-77.
20. Tlegenov AE. The effectiveness of treatment of diabetic polyneuropathy in vitamin B. Medicine 2013; (10): 40-2 (In Russ.)
21. Umerova AR, Dorfman IP, Orlova EA. Modern approaches to treatment of diabetic polyneuropathy. Russian Medical Journal 2015; (26): 1538-42 (In Russ.)
22. Caram-Salas NL, Reyes-Garcia G, Medina-Santillan R, Granados-Soto V. Thiamine and cyanocobalamin relieve neuropathic pain in rats: synergy with dexamethasone. Pharmacology 2006; 77(2): 53-62.
23. Mixcoatl-Zecuatl T, Quinonez-Bastidas GN, Caram-Salas NL, Ambriz-Tututi M, Araiza-Saldana CI, Rocha-Gonzalez HI et al. Synergistic antiallodinic interaction between gabapentin or carbamazepine and either benfotiamine or cyanocobalamin in neuropathic rats. Methods Find Exp Clin Pharmacol. 2008; 30(6): 431-41.
24. Granados-Soto V, Sanchez-Ramirez G, La Torre MR, Caram-Salas NL, Medina-Santillan R, Reyes-Garcia G. Effect of diclofenac on the antiallodinic activity of vitamin B12 in a neuropathic pain model in the rat. Proc West Pharmacol Soc. 2004; 47: 92-4.
25. Hung KL, Wang CC, Huang CY, Wang SJ. Cyanocobalamin, vitamin B12, depresses glutamate release through inhibition of voltage dependent Ca2+ influx in rat cerebrocortical nerve terminals. Eur J Pharmacol. 2009; 602(2-3): 230-7.
26. Strokov IA, Akhmedzhanova LT, Solokha OA. Efficacy of B vitamins in the treatment of pain syndromes. Russian Medical Journal 2010; (16): 1014-7 (In Russ.)
27. Montero J, Danilov AB. The role of nucleotides in the treatment of peripheral neuropathy. Manage Pain 2015; (4): 33-8 (In Russ.)
Review
For citations:
Demidova O.A., Shikh E.V. ANALGESIC POTENTIAL OF PURINE RECEPTOR AGONISTS AND B VITAMINS IN THE TREATMENT OF DIABETIC POLYNEUROPATHY. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2018;8(1):17-22. (In Russ.) https://doi.org/10.30895/1991-2919-2018-8-1-17-22
Views:
930
Email this article 